113,192 Shares in Gilead Sciences, Inc. $GILD Purchased by EP Wealth Advisors LLC

Key Points

• EP Wealth Advisors LLC acquired 113,192 Gilead shares during the second quarter, valued at approximately $14.3 million. Institutional investors collectively own 83.67% of the company.
• Gilead reported quarterly revenue of $7.8 billion, exceeding estimates, while adjusted EPS of negative $6.75 also topped expectations. Revenue increased 10.6% year over year.
• The company declared a quarterly dividend of $0.82 per share, equivalent to an annualized $3.28 payout and a 2.2% yield. Meanwhile, insiders sold 87,000 shares worth about $11.6 million over the past 90 days, and analysts maintain a “Moderate Buy” consensus with a $158.04 target price.

EP Wealth Advisors LLC acquired a new stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The fund acquired 113,192 shares of the biopharmaceutical company's stock, valued at approximately $14,301,000.

Several other institutional investors have also added to or reduced their stakes in the business. Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences in the fourth quarter worth about $25,000. Persistent Asset Partners Ltd purchased a new stake in shares of Gilead Sciences during the 2nd quarter valued at approximately $25,000. Vermillion & White Wealth Management Group LLC lifted its stake in shares of Gilead Sciences by 71.4% during the 4th quarter. Vermillion & White Wealth Management Group LLC now owns 204 shares of the biopharmaceutical company's stock valued at $25,000 after buying an additional 85 shares in the last quarter. Quattro Advisors LLC bought a new position in Gilead Sciences in the 4th quarter worth approximately $26,000. Finally, Wealth Preservation Advisors LLC grew its stake in Gilead Sciences by 60.0% in the 4th quarter. Wealth Preservation Advisors LLC now owns 216 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 81 shares in the last quarter. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, CEO Daniel Patrick O'day sold 15,000 shares of the business's stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $130.31, for a total transaction of $1,954,650.00. Following the completion of the transaction, the chief executive officer owned 592,133 shares of the company's stock, valued at approximately $77,160,851.23. The trade was a 2.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew D. Dickinson sold 3,000 shares of the company's stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $138.36, for a total transaction of $415,080.00. Following the completion of the transaction, the chief financial officer owned 165,646 shares in the company, valued at approximately $22,918,780.56. This trade represents a 1.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 87,000 shares of company stock worth $11,562,960. Insiders own 0.30% of the company's stock.

Gilead Sciences Stock Up 1.9%

GILD opened at $146.12 on Friday. The company has a fifty day moving average price of $131.97 and a 200-day moving average price of $136.59. The firm has a market capitalization of $181.18 billion, a P/E ratio of -54.73 and a beta of 0.32. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. Gilead Sciences, Inc. has a one year low of $108.46 and a one year high of $157.29.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The company had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same quarter last year, the business posted $2.01 earnings per share. The firm's revenue was up 10.6% compared to the same quarter last year. Equities research analysts expect that Gilead Sciences, Inc. will post -0.51 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.82 per share. This represents a $3.28 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Tuesday, September 15th. Gilead Sciences's dividend payout ratio (DPR) is -122.85%.

Analyst Upgrades and Downgrades

GILD has been the topic of a number of analyst reports. Leerink Partners cut shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and lowered their target price for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Truist Financial cut their price target on Gilead Sciences from $157.00 to $156.00 and set a "buy" rating for the company in a report on Tuesday, July 7th. Daiwa Securities Group decreased their price objective on Gilead Sciences from $161.00 to $150.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 19th. Wall Street Zen raised Gilead Sciences from a "hold" rating to a "buy" rating in a report on Saturday, August 15th. Finally, Barclays cut their target price on Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 29th. Twenty-four investment analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company. According to MarketBeat, Gilead Sciences currently has an average rating of "Moderate Buy" and a consensus price target of $158.04.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead's product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source